← All trials
NCT01571505
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2012
- Primary completion
- Jul 1, 2015
- Completion date
- Sep 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 372
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- International Vaccine InstituteLead sponsor
- International Vaccine InstituteOverall official - principal investigator
- University of VirginiaOverall official - principal investigator
- University of VermontOverall official - principal investigator
- National Institute of Cholera and Enteric Diseases, Kolkata, IndiaOverall official - principal investigator
- University of VirginiaCollaborator
- University of VermontCollaborator
- Bill and Melinda Gates FoundationCollaborator
- National Institute of Cholera and Enteric Diseases, Kolkata, IndiaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.